Paul Gettys Corn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paul Gettys Corn has a total of 190 co-authors. Here are the top co-authors by number of shared publications:
- Christopher J. Logothetis
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
160 shared publications - Ana M. Aparicio
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
153 shared publications - Patricia Troncoso
The University of Texas MD Anderson Cancer Center, Houston, USA
153 shared publications - Patrick G. Pilie
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
138 shared publications - Amado Zurita-Saavedra
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA
127 shared publications - Bradley M. Broom
Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
109 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods S1 from A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture
Supplementary Methods file contains extended methods, including the processing and analysis of multiple sequencing datasets.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods S1 from A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture
Supplementary Methods file contains extended methods, including the processing and analysis of multiple sequencing datasets.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S6 from A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture
Supplementary Tables file contains key information and supporting datasets. Table S1 | Clinicopathological features of the 22 MIBC patients. Table S2 | The top 50 most significantly differentially expressed genes between the 15 single cell clusters. Table S3 | GSEA pathway enrichment results for 4 spatial clusters. Table S4 | Clinical characteristics and spatial tumor state composition across samples. Table S5 | Bootstrap-based robustness analysis of spatial tumor state proportions. Table S6 | The top 50 most significantly differentially expressed genes between the 4 spatial clusters.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S6 from A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture
Supplementary Tables file contains key information and supporting datasets. Table S1 | Clinicopathological features of the 22 MIBC patients. Table S2 | The top 50 most significantly differentially expressed genes between the 15 single cell clusters. Table S3 | GSEA pathway enrichment results for 4 spatial clusters. Table S4 | Clinical characteristics and spatial tumor state composition across samples. Table S5 | Bootstrap-based robustness analysis of spatial tumor state proportions. Table S6 | The top 50 most significantly differentially expressed genes between the 4 spatial clusters.
- Open Access
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S15 from A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture
Supplementary Figures file contains Supplementary Figures S1–S15. Figure S1 | Pathology-guided spatial annotation across 22 MIBC tumors. Figure S2 | Validation of spatial deconvolution accuracy and cell-type compartmentalization. Figure S3 | Additional tumors demonstrating spatial CNV-based subclones and transcriptional divergence. Figure S4 | Cross-platform concordance of CNV profiles inferred from spatial transcriptomics and WES. Figure S5 | Transcriptional and functional features across the luminal-to-basal differentiation continuum. Figure S6 | Single-cell analysis recapitulates the spatial luminal-to-basal differentiation continuum. Figure S7 | Spatial validation of lineage-associated EGFR and FGFR3 expression patterns. Figure S8 | Lineage-associated expression of FGFR3–EGFR signaling and transcriptional regulators across normal tissue, tumor states, and independent cohorts. Figure S9 | Pathology-guided spatial annotation across all MIBC tumors. Figure S10 | Spatial tumor states associate with chemotherapy response and stress-related gene expression. Figure S11 | NECTIN4 expression is enriched in luminal tumors and declines at the tumor-normal boundary. Figure S12 | Subtype-associated genomic alterations and their relationship with basal program activity. Figure S13 | Associations between basal signature scores and clinical or molecular features across MIBC cohorts. Figure S14 | Pathologist-guided TLS annotation confirms spatial transcriptomic predictions. Figure S15 | Lineage-associated chemokine programs and tumor–TLS interactions.
- 1 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S15 from A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture
Supplementary Figures file contains Supplementary Figures S1–S15. Figure S1 | Pathology-guided spatial annotation across 22 MIBC tumors. Figure S2 | Validation of spatial deconvolution accuracy and cell-type compartmentalization. Figure S3 | Additional tumors demonstrating spatial CNV-based subclones and transcriptional divergence. Figure S4 | Cross-platform concordance of CNV profiles inferred from spatial transcriptomics and WES. Figure S5 | Transcriptional and functional features across the luminal-to-basal differentiation continuum. Figure S6 | Single-cell analysis recapitulates the spatial luminal-to-basal differentiation continuum. Figure S7 | Spatial validation of lineage-associated EGFR and FGFR3 expression patterns. Figure S8 | Lineage-associated expression of FGFR3–EGFR signaling and transcriptional regulators across normal tissue, tumor states, and independent cohorts. Figure S9 | Pathology-guided spatial annotation across all MIBC tumors. Figure S10 | Spatial tumor states associate with chemotherapy response and stress-related gene expression. Figure S11 | NECTIN4 expression is enriched in luminal tumors and declines at the tumor-normal boundary. Figure S12 | Subtype-associated genomic alterations and their relationship with basal program activity. Figure S13 | Associations between basal signature scores and clinical or molecular features across MIBC cohorts. Figure S14 | Pathologist-guided TLS annotation confirms spatial transcriptomic predictions. Figure S15 | Lineage-associated chemokine programs and tumor–TLS interactions.
- Open Access
- 1 July 2026
- Published by Wiley in CA: A Cancer Journal for Clinicians
- Vol. 76 (4)
Discordant molecular biomarkers in unfavorable intermediate‐risk localized prostate cancer
- 1 July 2026
- Published by Wiley in CA: A Cancer Journal for Clinicians
- Vol. 76 (4)
Open AccessDiscordant molecular biomarkers in unfavorable intermediate‐risk localized prostate cancer
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S13 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S13. Tumor subclone changes in longitudinal ctDNA samples: P182, P190, P196, P198, P203, and P204
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S13. Tumor subclone changes in longitudinal ctDNA samples: P182, P190, P196, P198, P203, and P204
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Cox proportional hazards model of the genomic aberrations and overall survival
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Cox proportional hazards model of the genomic aberrations and overall survival
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S11. Tumor subclone changes in longitudinal ctDNA samples: P126, P127, P131, P132, P138, and P142
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S11. Tumor subclone changes in longitudinal ctDNA samples: P126, P127, P131, P132, P138, and P142
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S6. Mutation signature and CNV signature changes in relation to treatments
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S6. Mutation signature and CNV signature changes in relation to treatments
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S2. Landscape of genomic aberrations in longitudinal plasma samples
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S2. Landscape of genomic aberrations in longitudinal plasma samples
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S22 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S22. Survival analysis of identified genomic alterations that related to chemotherapy resistance or shorter PFS of chemotherapy in cBioPortal
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S22 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure S22. Survival analysis of identified genomic alterations that related to chemotherapy resistance or shorter PFS of chemotherapy in cBioPortal